key: cord-0771248-drvwxce9
authors: Alimohammadi, Reza; Porgoo, Meysam; Eftekhary, Mohamad; Kiaie, Seyed Hossein; Dezfouli, Ehsan Ansari; Dehghani, Maryam; Nasrollahi, Kaveh; Malekshahabi, Talieh; Heidari, Maryam; Pouya, Sedigheh; Alimohammadi, Masoumeh; Khavas, Dorsa Sattari; Modaresi, Mohammad Sadra; Ghasemi, Mohammad Hossein; Ramyar, Hamed; Mohammadipour, Fatemeh; Hamzelouei, Fateme; Mofayezi, Ahmadreza; Mottaghi, Seyed Saeed; Rahmati, Amirhosein; Razzaznian, Mohsen; Tirandazi, Vista; Borzouee, Fatemeh; Sadeghi, Hossein; Mohammadi, Melika Haji; Rastegar, Leila; Safar Sajadi, Seyed Milad; Ehsanbakhsh, Hossein; Bazmbar, Hamed; Nouraee, Maedeh Shams; Pazooki, Pouya; PahlevanNeshan, Mina; Alishah, Khadijeh; Nasiri, Fateme; Mokhberian, Neda; Mohammadi, Seyedeh Shima; Akar, Shima; Niknam, Hamidreza; Azizi, Marzyieh; Ajoudanian, Mohammad; Moteallehi-Ardakani, Mohammad Hossein; Mousavi Shaegh, Seyed Ali; Ramezani, Reihaneh; Salimi, Vahid; Moazzami, Reza; Hashemi, Seyed Mahmoud; Dehghanizadeh, Somaye; Khoddami, Vahid
title: mRNA-based vaccine candidate COReNAPCIN® induces robust humoral and cellular immunity in mice and non-human primates
date: 2022-03-07
journal: bioRxiv
DOI: 10.1101/2022.03.05.483092
sha: 295dbf0a0c65a2ad35ac40f8195cb2dc7c6a2ede
doc_id: 771248
cord_uid: drvwxce9

At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2×108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the beta coronavirus genus, and since its emergence in 2019 leads to hundreds of millions of cases of Coronavirus Disease 2019 and several millions of deaths so far 1, 2 . Unlike other members of beta coronavirus genus which led to substantial human disease in the last 20 years, SARS-CoV-2 has airborne transmission effectively spreading between individuals 3, 4 . Despite of rapid development of vaccines against SARS-CoV-2, there is still a substantial worldwide shortage of effective vaccines, especially with rapid emergence and global spread of new SARS-CoV-2 variants 5 .

In the past two years several vaccine platforms have been developed to prevent SARS-CoV-2, among which the mRNA technology, due to some unique features, appears to be the most efficient platform 6 . Notably the high-speed, scalable and flexible production of mRNA vaccines is critical for the rapid response to pandemic conditions. Only few weeks can take from receiving the genetic code of a particular antigen to the design and production of mRNA vaccines in a prepared platform, an important feature especially for generation of variantspecific vaccines in the case of COVID-19 [7] [8] [9] [10] . Beside unique advantages in the development and mass production phases, the mRNA vaccines have been shown to generate the most efficient and safest vaccines 11 . This is primarily due to the in-vivo translation of mRNAs into the target protein, ensuring the correct folding and natural glycosylation pattern of the encoded antigen. Additionally, both humoral and cellular immunity are efficiently elicited using mRNA vaccines, generating the most effective vaccines against viruses including SARS-CoV-2 12 .

Notably, while formulation of mRNA vaccines is free of adjuvants, increasing their safety indices, the chemical nature of foreigner mRNA molecules entering the cells from outside confers a significant intrinsic adjuvant-like activity to mRNA vaccines efficiently enhancing both innate and adaptive immune responses. Moreover, due to their transient mode of action there is no concern about integration of mRNA codes into the genomic DNA 13 . Overall, the mRNA technology, recently proven by at least two approved and globally tested mRNA vaccines, introduces an efficient strategy to obtain the highest level of both humoral and cellular immunity against a particular infectious agent, in parallel with the highest safety indices, making it one of the best platforms for vaccine development.

SARS-CoV-2 Spike protein (S protein), the primary target for neutralizing antibodies, is a heavily glycosylated protein that orchestrates the entrance of the virus into the host cells.

During cell fusion, the S protein undergoes conformational change and facilitates the insertion of virus genome into the host cells 14, 15 . This change in the original 3 dimensional (3D) structure of S protein may have a catastrophic effect on S protein immunogenicity 16 . One way to increase the immunogenicity of S protein is the substitution of two proline residues at the apex of the central helix and heptad repeat 1 of the spike glycoprotein to stabilize it at its native prefusion conformation 17, 18 .

Here we present the preclinical report of COReNAPCIN ® , a modified mRNA vaccine candidate formulated in lipid nanoparticles (LNPs) for expression of the prefusion-stabilized form of SARS-CoV-2 spike glycoprotein upon intramuscular injection, in rodents and nonhuman primates.

To make COReNAPCIN ® the nucleoside modified mRNA encoding prefusion stabilized form of SARS-CoV-2 Spike glycoprotein was designed and produced. The 2P mutation was used to stabilize the spike protein in the prefusion conformation to increase the efficiency of immunologic response against viral infection ( fig. 1a&b ). The COReNAPCIN ® coding sequence was designed based on a special codon optimized template for maximizing the protein expression (by substituting the rare codons with common triplets) and minimizing the intracellular immunity (by reducing the uridine stretches within the sequence). Additionally for further stabilization of the mRNA transcripts and elimination of the unfavorable immunogenic responses all remaining uridines within the sequence were substituted with N1-methylpseudouridine during the mRNA synthesis step. After assessment of RNA integrity and purity further confirmed the uniformity in shape and size of nanoparticles and validated their expected LNP-specific morphology. RNA encapsulation efficiency (EE%) of mRNA-LNPs was analyzed semi quantitatively using gel retardation assay and quantitatively using a fluorescentbased method showing EE% of more than 90 (Table s1) . For in-vitro functional analysis following addition of mRNA-LNPs to cultured HEK-293 cells the expression of SARS-CoV-2 Spike glycoprotein-2P at the cell surface was evaluated by flow cytometry using spikespecific antibodies ( fig. 1h ). Further validation of correct protein translation was performed by Western Blotting (fig. 1i ). After full characterization COReNAPCIN ® was used for assessment of immunity in C57BL/6 and BALB/c mice and rhesus macaque (see below).

In order to evaluate the immunogenicity of vaccine candidate, the humoral and cellular 2g, the neutralization antibody concentration detected by sVNT, reached 40 µg/ml (detection limit of kit) in all mice except two C57BL/6 mice.

There are accumulating lines of evidence which support a role for T cells in immunity against COVID-19 19 . Furthermore, sufficient T cell responses are needed for orchestrating potent antibody responses. Therefore, we analyzed the cellular immune response in mice following the COReNAPCIN ® vaccination. Consistent with humoral responses, the induced cellular immunity presented by intracellular cytokine staining and/or ELISpot also exhibited dosedependency ( fig. 3 ). To explore the S specific T cell responses by intracellular cytokine staining, we stimulated splenocytes from two mice strains with SARS-CoV-2 Spike peptide pool and conducted flow cytometry to quantify the number of Spike specific T cell populations.

The frequency of CD44 high IFN-γ + , CD4 + IFN-γ + , and CD8 + IFN-γ + T cells were significantly indicating a strong Th1 response over Th2 and thus further confirming that COReNAPCIN ® vaccination elicits a Th1-biased immune response.

Next, we investigated the COReNAPCIN ® immunogenicity in rhesus macaques through the same experiments performed in mice. Six rhesus macaques were i.m. injected with two doses of 30 or 50 µg COReNAPCIN ® or of PBS with 28 days interval. As shown in the fig. 5b , regardless of the vaccination dose, the anti S specific IgG seroconversion was observed by day endpoint titer of 1.5×10 6 and 1.5×10 7 , respectively after the 30 and 50 µg of COReNAPCIN ® .

Although the anti S antibody waned overtime, its reciprocal endpoint titer was remained more than 10 5 up to day 91 post prime ( fig. 5b ).

We also assessed the anti-RBD-specific IgG binding antibody endpoint titer in rhesus macaques. Same as the anti-Spike antibody, the RBD-specific IgG antibody titer reached its 

For evaluating the protective capacity of COReNAPCIN ® , rhesus macaques, as an infection model for SARS-CoV-2, were subjected to a challenge study in which they were intranasally and intratracheally inoculated with 2×10 8 6a ). This data is in line with the findings of viral genes RT-qPCR, and indicates the protective immunity induction by candidate vaccine. The qPCR and histopathology data support the protective effect of the COReNAPCIN ® candidate vaccine in preventing monkeys from being infected with SARS-CoV-2.

After more than two years of COVID-19 experience now billions of people around the world are vaccinated based on different vaccine platforms 1, 5 . However, despite the effectiveness of vaccines against ancestral strain, due to the rapid emergence of variant of concerns (VOCs) and also the observed waning immunity, most probably the majority of vaccinated people will require regular booster doses at least in the next few years to overcome this health threatening issue [21] [22] [23] . This is true even for people vaccinated with the most effective vaccines; mRNA-1273 & BNT162b, and a similar situation is expected for convalescent people recovered from COVID-19 [24] [25] [26] [27] . Moreover, due to the high mutation rate and behavior of SARS-CoV-2 circulating between humans and animals, scientists predict COVID-19 will remain a major health challenge probably for the next decade 28, 29 . These facts highlight the importance of access to scalable vaccine production platforms for complete eradication of this devastating disease. Therefore, billions of doses will be required annually not only as primary or booster doses for current human population but also for protection of newborns.

As explained earlier, among the different platforms of SARS-CoV-2 vaccines tested so far, In mice, immunization with COReNAPCIN ® rapidly elicited high anti-S and anti-RBD binding and neutralizing antibody titers 35, 36 . The neutralizing capacity of high titer antibodies induced by COReNAPCIN ® were confirmed by pVNT and sVNT. COReNAPCIN ® also induced strong T cell responses in mice. Both SARS-CoV-2 specific IFN-γ + CD4 + and IFN-γ + CD8 + T cells were induced by COReNAPCIN ® in mice. Activation of cellular immunity is an important feature of mRNA vaccines especially against new variants, and has also been observed with adenovirus based vaccines 37, 38 . However, repeated booster doses of adenoviral vaccines is still under question due to immunity against the vector itself, while mRNA vaccines can be used repeatedly 39, 40 . Th1 polarizing vaccines, will reduce the risk of VARED during viral infection 41 . Following COReNAPCIN ® injection, a robust Th1-polarized T cell response was observed in BALB/c mice which was confirmed by the balanced IGg2a/IgG1 ratio and IFN-γ production after restimulation with SARS-CoV-2 peptide.

In rhesus macaques, COReNAPCIN ® induced strong humoral immunity with the mean neutralizing antibody titer in vaccinated rhesus macaques about 13 folds higher than the titer in convalescent patients (data not shown). COReNAPCIN ® also induced a robust cellular immune response with similar immune profile observed in mice. As in mice, Th1 over Th2 Additionally, COReNAPCIN ® variant specific vaccines against major variants of concern are constantly under development and preclinical testing and their outcomes will be presented in future. 

Following mRNA purification, mRNA was diluted in citrate buffer (pH 4) to reach the desired concentration. Lipid mixture (lipid mix) solution was prepared (12. 

In order to analyze transfected cells for cell surface expression of S protein, 2×10 5 

Rhesus macaques were housed individually in cages in a climate-controlled room (temperature of 18-25 °C and humidity 30-70%), with a 12 h light/dark cycles, given chow and fruits in strict accordance to the animal welfare requirements and allowed free access to water. During the challenge study, macaques were housed in the biosafety level 3 (BSL3) facility.

Each group was made of 2 rhesus macaques (1 male and 1 female) injected with either PBS, 30 or 50 µg of mRNA-LNP into the right hind leg (IM) at days 0 and 28. Blood samples were collected and subjected for analyzing humoral immune responses. Cellular immunity was assessed at day 21 post boost injection. The rhesus macaque immunogenicity study design, is illustrated in fig. 5a. 

To detect and measure the presence of SARS-CoV-2 viral RNA in nasal turbinates and rectal swab samples of macaques, two SARS-CoV-2 genes, N and RdRp genes, were analyzed by qPCR test, using SENMURV multi-star SARS-CoV-2 RT-PCR kit (STRC). Nasal and rectal swab specimens were subjected to total RNA extraction using the RNeasy Mini Kit (QIAGEN).

The qRT-PCR reaction, was run with the following thermal profile: 20 min in 50°C, 10 min in 95°C, and followed by 40 cycles of 95°C and 55°C for 10 and 40 s, respectively. 

Spike pseudotyped lentivirus, produced by the co-transfection of plex307-egfp, pCMV3-spike (Wuhan-D614G), and pspax2 with Lipofectamine 3000 (Thermo). Spike pseudotyped lentivirus encodes the EGFP protein that serves as a reporter gene. pVNT test performed as previously described by Ferrara et.al 45 

The cVNT assay, was conducted on serum samples of rhesus macaques, collected on day 14 post boost. Briefly, 50 μL of 100 median tissue culture infecting dose per mL (TCID50/mL) of SARS-CoV-2, were mixed with 50 μL of two-fold serial dilutions of heat-inactivated serum (at 56°C for 30 min). After 60 min incubation at 37°C, the virus-serum mixture was added to 96 well-plate previously seeded with 1.5 × 10 4 Vero cells per well (performed in triplicate).

One hour post-incubation, the supernatant was removed and cells were washed twice with Dulbecco's Modified Eagle Medium (DMEM). Then, cells were incubated for 72 hrs at 37°C in a 5% CO2 in DMEM with 10% heat-inactivated Fetal bovine serum (FBS). Half-maximal inhibitory concentration (IC50) titer, was measured by microscopy and reported as the highest dilution inhibiting 50% cytopathic effect (CPE) formation.

We used sVNT (ACE2 inhibition test) ELISA (Pishtaz Teb) (with a detection limit of 40 µg/ml), for measuring the SARS-COV-2 neutralizing ability of serum samples of mice and rhesus macaques collected 40 days post-prime. The assay was performed according to the manufacturer's instructions; in summary, 50µl of serum samples, negative and positive controls were added to the wells. Then immediately, 50µl RBD conjugated HRP, was added and incubated for 30 min at 37°C. Following the routine wash, 100 µl TMB was added to each well and plates were placed at room temperature for 15 min. Finally, 100 µl 1N HCL as stop solution was added to each well and the absorbance was measured by BioTek® 800 ™ TS at 450 nm and 630 nm (as Reference filter).

Mice fresh splenocytes were separated by mechanical homogenization then filtered through a 

Cryopreserved mice splenocytes were thawed in pre warmed RPMI (Biowest) and rested for 24 h. IFN-γ ELISpot precoated plates (Abcam) were used according to the manufacturer's instruction. Briefly, the total number of 2×10 5 harvested splenocytes, were stimulated with 2 µg/ml of SARS-CoV-2 peptide pool (JPT product PM-WCPV-S-1, Germany), for 18 hrs at 37°

C. DMSO (Sigma-Aldrich, USA) and phytohemagglutinin (PHA) (Gibco) were used as negative and positive control, respectively. After several wash steps, 100 µl streptavidin-AP (Abcam) was added to each well, followed by incubation at room temperature for 1 hour.

Finally, 100 µl BCIP/NBT was added to the each well and after 15 min incubation at room temperature, plate was rinsed in tap water, dried and spots were counted by image processing software. 

Graph Pad V8 Prism was used to illustrates the figures and analyze the results statistically.

Dotted lines indicate assay limits of detection. For comparing values between two groups, ttest was conducted and Group comparisons were made by one-way ANOVA followed by Dunn's test. A p value less than 0.05 (*P <.05, **P <.01, ***P <.001, ****P <.001) was assumed to be statistically significant.

We responses of splenocytes to S1 SARS-CoV-2 peptide pool (as duplicate), S2 SARS-CoV-2 peptide pool (as duplicate), DMSO (a negative control), and PHA (an unspecific positive control). Each row represents an individual mouse. ). A p value less than 0.05 (*P <.05, **P <.01, ***P <.001) was assumed to be statistically significant. . c-d) Splenocytes from BALB/c and C57BL/6 mice (n = 5 each group) were exposed to SARS-CoV-2 Spike peptide pool for 24 hrs and the level of IFN-γ and IL-4 cytokines in the cell culture supernatants were determined through ELISA. ). A p value less than 0.05 (*P <.05, ****P <.0001) was assumed to be statistically significant. (g-h) , after 24 hrs stimulation with SARS-CoV-2 peptide pool (S1 and S2), the frequency of IFN-γ producing cells per 10 6 splenocytes were quantified (h). In (g), the representative images of ELISpot wells, columns from left to right are: responses of PBMCs to S1 and S2 SARS-CoV-2 peptide pool (as duplicate), DMSO (a negative control), and Anti CD3 (an unspecific positive control). Each row represents an individual rhesus macaque. An ELISA assay (i) was used to assess the IFN-γ (square shape symbol, □) and IL-4 (circle shape symbol, •) cytokine level in the cell culture supernatants following 8 hrs stimulation with SARS-CoV-2 peptide pool. 

An interactive web-based dashboard to track COVID-19 in real time

The COVID-19 Pandemic: A Comprehensive Review of

COVID-19: Emergence, Spread, Possible Treatments, and Global Burden

An interactive website tracking COVID-19 vaccine development

The dawn of mRNA vaccines: The COVID-19 case

mRNA-Based Vaccines

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

The promise of mRNA vaccines: a biotech and industrial perspective

Novel Vaccine Technologies

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network metaanalysis

COVID-19 vaccines: modes of immune activation and future challenges

Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-. )

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science (80-. )

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

T cell responses in patients with COVID-19

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

The Future of SARS-CoV-2 Vaccination -Lessons from Influenza

Beyond Omicron: what's next for COVID's viral evolution

Modelling vaccination strategies for COVID-19

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity

Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer

Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

The T cell immune response against SARS-CoV-2

mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. npj Vaccines

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines

Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Stabilizing the closed SARS-CoV-2 spike trimer

A statistically defined endpoint titer determination method for immunoassays

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis